A Study of TAK-510 in Healthy Adults: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of TAK-510 in Healthy Adults (NCT04731922), a randomized phase 1 study. The primary outcome is Parts 1 and 2: Number of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose.

2. Clinical Question

The study was registered as a Phase 1 trial in healthy participants, although the brief summary describes TAK-510 in relation to nausea and vomiting. That description does not make this a trial of symptom relief in people experiencing those symptoms: the listed condition is Healthy Participants, and the stated primary endpoint concerns vital-sign safety criteria. The registry record does not report a primary efficacy endpoint or results comparing symptom outcomes.

3. Trial Design

The registry record describes a randomized, double-blind, placebo-controlled, sequential Phase 1 study. Its stated aims were to assess safety, tolerability, and pharmacokinetics of TAK-510 in healthy subjects. Enrollment was 124, and the record lists the study status as completed. The study start date was 2021-02-03, and the primary completion date was 2022-07-24.

The brief summary divides participation into three parts, with each participant taking part in only one part. Part 1 involved a single injection, while Part 2 involved injections once daily for 5 days. The arm descriptions specify daily dosing from Days 1 to 7 in Part 3 and refer to dose titration and redosing cohorts. The record describes staggered dosing in Part 1 and says dose decisions for later cohorts were informed by emerging safety, tolerability, and available pharmacokinetic data. Complete details of the dosing plan are not reported in the registry record.

Randomization and double masking identify important design features, but the registry record does not report the allocation ratio, the method used to generate the random sequence, or who was masked. The sequential model and dose cohorts also mean that the study is described as a series of staged evaluations rather than a single simple comparison at one fixed dose. The record does not report a statistical plan for comparing all dose cohorts or for combining information across the three parts.

The listed intervention groups include TAK-510 and TAK-510 placebo. Safety outcomes were collected across study parts, with the primary endpoint specified for Parts 1 and 2. The registry record lists 34 outcome measures but no analyses. It does not provide a complete participant flow, group-specific primary endpoint results, or a detailed account of how the sequential decisions were made.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Healthy participants were enrolled in study into 2 Parts: Single Rising Doses (SRD) (Part 1) and Multiple Rising Doses (MRD) (Part 2) to receive TAK-510 placebo-matching or TAK-510 injection. Starting Dose 1 was 5 micrograms (mcg) and subsequent doses were increased from low dose to high dose for Doses 1-11 and Doses 1A-4A in Part 1 or Part 2, respectively. Study was completed after completion of Parts 1 and 2. Sponsor decided not to conduct Part 3 after comprehensive review of available data.

Only the first 6 of 17 groups are shown.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The safety analysis set included all participants who were randomized and received at least 1 dose of study treatment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The safety analysis set included all participants who were randomized and received at least 1 dose of study treatment.

Only the first 6 of 18 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Parts 1 and 2: Number of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose, measured over Parts 1 and 2: From the first dose of study drug up to Day 29.

The primary endpoint is the number of participants in Parts 1 and 2 who met markedly abnormal criteria for vital-sign measurements at least once after a dose. The specified timeframe runs from the first dose of study drug up to Day 29. Measurements included systolic and diastolic blood pressure, body temperature, pulse rate, respiratory rate, orthostatic blood pressure, and orthostatic pulse rate.

The registry record defines marked abnormality using thresholds for low and high measurements and specified changes on standing. These criteria allow the endpoint to count participants who cross a prespecified safety threshold, rather than describing the average value across the group. For example, a participant is counted if a qualifying finding occurs at least once; the endpoint does not, by itself, indicate how often a finding occurred, how long it lasted, or whether it was clinically important to an individual.

This kind of endpoint is used in an early-phase safety assessment to monitor vital signs after exposure and to identify participants meeting predefined criteria. It is not an efficacy measure and does not establish the cause of an abnormal reading. The registry record defines the safety analysis set as randomized participants who received at least 1 dose of study treatment. The primary endpoint's participant counts and any comparison between TAK-510 and placebo are not reported in the registry record, so the endpoint definition alone cannot show what was observed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies the primary outcome as a count of participants who met a predefined safety criterion at least once. This is a binary participant-level outcome: for each person, the question is whether the criterion was met or was not met during the stated observation period. The reported group result would ordinarily be a count, with a denominator describing how many participants were assessed. Neither the primary outcome counts nor its group-specific denominators are reported in the registry record.

What does a participant count convey?

A count describes the number of people with an event, not the number of separate event episodes. If a participant meets the vital-sign criteria more than once, the endpoint still counts that participant once. This makes the outcome relatively straightforward to interpret, but it does not describe recurrence, duration, severity beyond the stated criteria, or the timing of the finding. Those details would require additional outcomes or participant-level information, which are not reported in the registry record.

Counts are often considered alongside denominators because the same count can mean different things in groups of different sizes. A proportion expresses the count relative to the participants assessed. A confidence interval can describe the statistical uncertainty around an estimated proportion or contrast. In general, confidence intervals are ranges of values compatible with the data and the method used; they are not guarantees that the true value lies within the reported range. No primary endpoint proportions, confidence intervals, or treatment contrasts are reported in the registry record.

How should cohort comparisons be approached?

Randomization is intended to support comparability between treatment groups, but interpretation also depends on allocation, the groups analyzed, and the analysis specified. This study is described as sequential and uses multiple dose cohorts, with later dose decisions informed by emerging safety, tolerability, and pharmacokinetic information. In general, results from separate cohorts should not automatically be treated as if they came from one concurrent, fixed-dose comparison. The registry record does not report an analysis plan explaining whether or how cohort results were combined or compared.

For a binary outcome, statistical methods may compare proportions or model the probability of an event. The appropriate approach depends on the design, the size and structure of the groups, and the prespecified estimand. In general, sparse event counts can make estimates imprecise and can challenge methods that rely on large-sample approximations. These are general considerations, not a description of an analysis performed in this trial. The registry record lists 0 analyses and does not identify an inferential method for the primary outcome.

What is the role of safety thresholds?

The endpoint uses marked-abnormality criteria for vital signs, including blood pressure, temperature, pulse, respiratory rate, and orthostatic measurements. Threshold-based endpoints provide a consistent rule for identifying values that merit safety attention within a study. A threshold crossing is not equivalent to a diagnosis, and the count does not establish that study treatment caused the finding. Causal interpretation would require examining the full design and the results by treatment group, as well as other clinical context. Those primary outcome results are not reported in the registry record.

Safety monitoring can produce many outcomes across body systems, measures, and timeframes. As a general matter, assessing many outcomes can increase the chance of observing an unusual finding by chance, particularly when separate statistical tests are performed. Methods for addressing this include prespecifying a hierarchy, controlling a family-wise error rate, or treating analyses as exploratory. The registry record lists 34 outcome measures but does not report a multiplicity strategy or a detailed statistical analysis plan. It is therefore not possible to determine whether formal adjustment was planned or performed.

What can planning calculations tell readers?

Planning calculations can illustrate the sample size needed under stated assumptions, including a chosen significance level, allocation, and effect size. Such calculations are not observed results and do not establish what a study was capable of detecting after it was conducted. The registry record describes a planning illustration based on the observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation. It also states that the effect considered is a stated fraction of the observed effect. The trial's own sample-size justification is not reported in the registry record, and no specific sample-size result is interpreted.

In general, planning illustrations depend on assumptions that may not match the actual design, particularly for a sequential study with multiple cohorts and safety outcomes. A sample-size calculation is distinct from observed power, which should not be used as a substitute for interpreting the estimate and its uncertainty. Since the primary endpoint estimates and their uncertainty are not reported in the registry record, no conclusion about precision or power for that endpoint can be drawn.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 34 outcome measures, including safety, vital-sign, electrocardiogram, laboratory, adverse-event, and antidrug-antibody outcomes. When many outcomes are assessed, some findings may occur by chance even if there is no underlying difference. As a general statistical principle, multiplicity procedures can control the chance of false-positive conclusions across a defined family of tests, while prespecified hierarchies can make clear which outcomes are confirmatory and which are exploratory. The registry record does not report a multiplicity strategy or a complete statistical analysis plan.

The record does not report interim analyses, stopping rules, or the decision rules used to move between dose cohorts. Although dose choices are described as informed by emerging safety, tolerability, and pharmacokinetic information, the specific procedures are not reported in the registry record. This distinction matters because a design's use of accumulating information does not by itself reveal how uncertainty or repeated decision-making was handled.

Missing-data methods and the extent of missing outcome data are not reported in the registry record. The record defines the safety analysis set as randomized participants who received at least 1 dose, but does not provide a primary endpoint analysis population count, participant flow, or details of how unavailable vital-sign measurements were handled. The primary endpoint results are also not reported, so completeness of endpoint measurement cannot be assessed.

The registry record does not report whether analyses were based on assigned treatment, treatment received, or another population beyond the stated safety set definition. It also does not report adjustment variables or a prespecified approach to dose-cohort comparisons. These omissions limit assessment of how the planned analyses address multiple outcomes, missing measurements, and the sequential structure.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The serious adverse event entries show 0 affected participants in every listed Part 1 and Part 2 group, and the death entries show 0 in every listed group. The entries include pooled placebo groups and TAK-510 dose cohorts. These figures describe the groups for which safety counts are listed; they do not report serious adverse event results for every study part or every outcome measure.

The registry also gives counts for other adverse events. Those counts are distinct from serious adverse events: an event classified as non-serious should not be read as a serious event, and the count alone does not describe its type, duration, or clinical importance. The listed other-event counts vary by cohort, but the registry record does not provide a complete narrative of those events or a comparative analysis.

Zero reported serious events is a descriptive observation, not proof that an event cannot occur. In general, the precision of a safety estimate depends on the number of participants assessed and the amount of follow-up, as well as the event definition. The safety population definition is randomized participants who received at least 1 dose, but complete event follow-up details are not reported in the registry record. These entries should therefore be interpreted as the reported counts, not as a definitive comparison of risk.

12. What the Result Does, and Does Not, Mean

The record establishes that TAK-510 was studied in a randomized, double-blind, placebo-controlled, sequential Phase 1 study in healthy participants, with safety, tolerability, and pharmacokinetics as stated aims. The primary endpoint was designed to count participants meeting predefined markedly abnormal vital-sign criteria after dosing in Parts 1 and 2. The registry record also reports cohort-level adverse event counts for selected groups.

It does not report the primary endpoint results, treatment-group contrasts, confidence intervals, or p-values. It therefore cannot show from the primary endpoint whether the number of participants meeting the vital-sign criteria differed between TAK-510 and placebo, or how precisely any such difference was estimated. The record also does not provide efficacy results for nausea or vomiting. Statements about symptom benefit or lack of benefit would not be supported by the reported information.

The zero serious adverse event and death counts in the listed cohorts are relevant descriptive observations, but they do not demonstrate that serious events are impossible or establish comparative safety. The listed groups are dose cohorts within a sequential study, and the record does not report an inferential analysis that accounts for cohort structure. The other adverse event counts should be interpreted separately from serious events and do not by themselves establish causation.

As a general principle, an early-phase safety study can characterize observed tolerability and inform further study design, but the strength of conclusions depends on complete outcome reporting and the precision of estimates. Here, key primary endpoint results and details of the statistical plan are not reported in the registry record. The appropriate interpretation is therefore limited to the stated design, endpoint definition, and safety counts that are listed, without extending those observations into an efficacy conclusion or a broad safety claim.

13. Why This Trial Matters Statistically

This study illustrates why early-phase trial results need to be read in the context of their design. The registry describes a sequential study with several dose cohorts, and later dose decisions were informed by emerging safety, tolerability, and pharmacokinetic information. In general, this structure can be useful for staged evaluation, but it also makes clear reporting of cohort definitions and decision rules important for interpreting comparisons.

The primary endpoint is a participant-level count based on predefined vital-sign thresholds. That choice yields an interpretable safety summary, while necessarily reducing detail about repeated events, timing, and duration. The distinction between an endpoint's operational definition and its observed results is essential: the record gives the definition, but does not report the primary endpoint counts or comparisons.

The record also demonstrates why zero counts require cautious interpretation. The listed groups report no serious adverse events and no deaths, but such entries remain descriptive and are not a substitute for uncertainty estimates or a comparison across treatment groups. Other adverse events are listed separately, reinforcing the need to distinguish event categories rather than treating all adverse events as interchangeable.

Statistically, the combination of multiple outcomes, multiple cohorts, and sequential decisions makes a prespecified analysis plan particularly relevant. The registry record does not report the multiplicity approach, missing-data handling, interim analysis procedures, or the statistical methods used for dose comparisons. This limits readers' ability to evaluate how results would have been selected and interpreted. The study is consequently useful as an example of the need to report not only design and endpoint definitions, but also outcome estimates, uncertainty, and analytical decisions.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary endpoint is defined in detail, but its observed counts and treatment-group results are not reported in the registry record. This prevents assessment of the primary safety question, including the size and precision of any group difference. The registry lists no analyses, so there is no reported inferential result to interpret.

The enrollment figure does not show how many participants were assessed for each outcome or included in each cohort. Although the safety analysis set is defined, participant flow, endpoint-specific denominators, and missing vital-sign data are not reported in the registry record. It is therefore not possible to assess outcome completeness or determine whether missing measurements could affect interpretation.

The study's sequential structure and dose cohorts are important limitations for simple cross-group interpretation. The registry describes decisions informed by emerging data but does not report the detailed dose-selection rules, interim procedures, or analysis methods. Complete details of the intervention schedules are also not reported in the registry record.

The record lists serious and other adverse event counts for selected groups, but does not provide a complete account of all safety results across all parts. The serious adverse event and death counts are descriptive; confidence intervals and comparative analyses are not reported. The multiplicity strategy, statistical plan, and missing-data methods are not reported in the registry record.

Finally, the listed population is healthy participants and the primary endpoint is a safety measure. The registry record does not report outcomes demonstrating changes in nausea or vomiting. Consequently, these data do not answer an efficacy question about those symptoms.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study of TAK-510 in Healthy Adults — NCT04731922.
• Registry record last updated 2024-03-04; status last verified 2023-07.
• Results first posted 2024-03-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04731922 is a completed, randomized, double-blind, placebo-controlled, sequential Phase 1 study of TAK-510 in healthy participants. Enrollment was 124. The study start date was 2021-02-03, and the primary completion date was 2022-07-24. The stated aims were to assess safety, tolerability, and pharmacokinetics.

The primary endpoint counted participants in Parts 1 and 2 who met markedly abnormal vital-sign criteria at least once after dosing, through Day 29. The safety analysis set included randomized participants who received at least 1 dose. Primary endpoint results and statistical analyses are not reported in the registry record.

For the listed Part 1 and Part 2 groups, serious adverse event counts and death counts are 0. Other adverse event counts are listed by cohort. These are descriptive safety entries, and the registry record does not report a comparative analysis or a complete account of results across all study parts.